5 assets in Ovarian Mucinous Cystadenocarcinoma

Therapeutic assets addressing Ovarian Mucinous Cystadenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Ovarian Mucinous Cystadenocarcinoma	Gynecologic Oncology Group	P3	BB (68)
Capecitabine Ovarian Mucinous Cystadenocarcinoma	National Cancer Institute (NCI)	P3	BB (66)
Oxaliplatin Ovarian Mucinous Cystadenocarcinoma	National Cancer Institute (NCI)	P3	B (62)
Adavosertib Ovarian Mucinous Cystadenocarcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Sapanisertib Ovarian Mucinous Cystadenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)